Table 1.
Summary of clinicopathological characteristics in the MPBCS cohort and their association with PAM50 subtypes#.
| Clinical parameter | Whole cohort n (%) | PAM50 | Cramer’s V/AOV | ||||
|---|---|---|---|---|---|---|---|
| LumA | LumB | Her2 | Basal | Normal | |||
| Number of subjects (%) | 1071 | 456 (42.6%) | 228 (21.3%) | 142 (13.3%) | 178 (16.6%) | 67 (6.3%) | |
| Age at diagnosis - mean (SD) | 54.5 (12.2) | 56.4 (12.4)a | 55.4 (13.4)a | 54.3 (11)a | 50.4 (10.8)b | 50.3 (9.6)b | p < 0.001 |
| Histological type | 0.1 (low) | ||||||
| Invasive (infiltrating) lobular carcinoma | 62 (5.8%) | 40 | 10 | 2 | 2 | 8 | |
| Invasive (inflitrating) ductal carcinoma | 919 (85.8%) | 372 | 197 | 134 | 162 | 54 | |
| Invasive mammary carcinoma (NOS) | 19 (1.8%) | 10 | 6 | 0 | 3 | 0 | |
| Invasive mixed ductal and lobular carcinoma | 24 (2.2%) | 13 | 7 | 0 | 1 | 3 | |
| Other | 47 (4.4%) | 21 | 8 | 6 | 10 | 2 | |
| Histological grade | 0.26 (medium) | ||||||
| Low | 128 (12%) | 100 | 10 | 5 | 4 | 9 | |
| Intermediate | 473 (44.2%) | 240 | 113 | 48 | 43 | 29 | |
| High | 431 (40.2%) | 98 | 94 | 85 | 130 | 24 | |
| Missing | 39 (3.6%) | 18 | 11 | 4 | 1 | 5 | |
| Clinical stage | 0.14 (low) | ||||||
| II A | 383 (35.8%) | 209 | 80 | 42 | 34 | 18 | |
| II B | 324 (30.3%) | 137 | 69 | 41 | 57 | 20 | |
| III A | 199 (18.6%) | 39 | 48 | 38 | 59 | 15 | |
| III B | 98 (9.2%) | 40 | 21 | 14 | 15 | 8 | |
| Missing/Other | 67 (6.3%) | 31 | 10 | 7 | 13 | 6 | |
| Lymph node status | 0.15 (low) | ||||||
| Positive | 556 (51.9%) | 191 | 120 | 84 | 123 | 38 | |
| Negative | 482 (45%) | 250 | 102 | 52 | 50 | 28 | |
| Missing | 33 (3.1%) | 15 | 6 | 6 | 5 | 1 | |
| Tumor size at diagnosis | 0.12 (low) | ||||||
| < = 20mm | 113 (10.6%) | 60 | 22 | 10 | 13 | 8 | |
| > 20-50mm | 666 (62.2%) | 311 | 140 | 83 | 98 | 34 | |
| > 50mm | 257 (24%) | 68 | 59 | 44 | 62 | 24 | |
| Missing | 35 (3.3%) | 17 | 7 | 5 | 5 | 1 | |
| ER status | 0.52 (high) | ||||||
| Positive | 800 (74.7%) | 442 | 223 | 56 | 33 | 46 | |
| Negative | 269 (25.1%) | 13 | 5 | 86 | 145 | 20 | |
| Missing/Indeterminate | 2 (0.2%) | 1 | 0 | 0 | 0 | 1 | |
| PgR status | 0.45 (high) | ||||||
| Positive | 670 (62.6%) | 398 | 175 | 37 | 18 | 42 | |
| Negative | 397 (37.1%) | 56 | 53 | 104 | 160 | 24 | |
| Missing/Indeterminate | 4 (0.4%) | 2 | 0 | 1 | 0 | 1 | |
| HER2 status | 0.39 (high) | ||||||
| Positive | 219 (20.4%) | 45 | 33 | 107 | 15 | 19 | |
| Negative | 843 (78.7%) | 407 | 191 | 35 | 163 | 47 | |
| Missing/Equivocal | 9 (0.8%) | 4 | 4 | 0 | 0 | 1 | |
| Ki67 (%) - median=30, range=0-100 | |||||||
| < = 20% | 422 (39.4%) | 284 | 54 | 38 | 19 | 27 | 0.32 (medium) |
| > 20% | 607 (56.7%) | 159 | 161 | 100 | 155 | 32 | |
| Missing/Indeterminate | 42 (3.9%) | 13 | 13 | 4 | 4 | 8 | |
#The whole cohort distribution is shown as absolute number of patients and percentage of the total, while distribution according to subtypes are shown in number of patients. AOV: analysis of variance. For age at diagnosis among different PAM50 subtypes, categories with significant differences (Tukey HSD, alpha = 0.05) are indicated by a change on the superindex letter (i.e. a vs b are significantly different). For the remaining variables, the association between each of them and PAM50 subtypes was always significant (chi-squared test, p < 0.001 in all cases). Hue represents the sign of the standardized chi-squared residual; red hue indicates higher observed than expected counts, and blue indicates lower observed than expected counts. Color saturation represents the absolute value of the standardized chi-squared residuals; more saturation indicates a larger deviation from the expected counts. Low, medium and high refer to the strength of the association seen between subtypes and the clinicopathological characteristics. A Cramer’s V value of 0.2 or less indicates a weak association, between 0.2 and 0.3 a moderate association and higher than 0.3 a strong association.